| Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| private:metacure | 131690 | May 29th, 2019 12:00AM | MetaCure | 291 | 12.00 | Open | Medical Devices | May 29th, 2019 07:24PM | May 29th, 2019 07:24PM | MetaCure, member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. MetaCure develops, produces and sells the DIAMOND therapy, an alternative to insulin, delivered by a proprietary implantable device system. DIAMOND is intended to treat type 2 diabetes in obese patients who are refractory to oral medication. The safety and efficacy of the DIAMOND therapy has been validated in clinical trials encompassing over 300 patients, which demonstrated it is as effective as insulin treatment while avoiding most of the associated side effects and avoiding the inconvenience of frequent blood tests and injections. DIAMOND is delivered by a pacemaker-like device implanted in the abdomen to deliver gentle electrical signals to the stomach when eating, which improves glycemic control and causes weight loss. The system has received CE mark and is approved for sale in Europe, Australia and other international markets. DIAMOND is not approved for use in the USA. For more information visit www.MetaCure.com | Open | Type 2 diabetes, Gastric Stimulation, Metabolic Syndrome, Diabesity, Medical device, Obesity, DIAMOND | Open | 101 Front Street | Hamilton | BM | MetaCure | Health Care | Health Care Equipment & Services | |||
| private:metacure | 131690 | Nov 7th, 2017 12:00AM | MetaCure | 260 | 13.00 | Open | Medical Devices | Nov 7th, 2017 05:59PM | Nov 7th, 2017 05:59PM | MetaCure, member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. MetaCure develops, produces and sells the DIAMOND therapy, an alternative to insulin, delivered by a proprietary implantable device system. DIAMOND is intended to treat type 2 diabetes in obese patients who are refractory to oral medication. The safety and efficacy of the DIAMOND therapy has been validated in clinical trials encompassing over 300 patients, which demonstrated it is as effective as insulin treatment while avoiding most of the associated side effects and avoiding the inconvenience of frequent blood tests and injections. DIAMOND is delivered by a pacemaker-like device implanted in the abdomen to deliver gentle electrical signals to the stomach when eating, which improves glycemic control and causes weight loss. The system has received CE mark and is approved for sale in Europe, Australia and other international markets. DIAMOND is not approved for use in the USA. For more information visit www.MetaCure.com | MetaCure | Health Care | Health Care Equipment & Services | |||||||||
| private:metacure | 131690 | Nov 1st, 2017 12:00AM | MetaCure | 258 | 13.00 | Open | Medical Devices | Nov 1st, 2017 05:42AM | Nov 1st, 2017 05:42AM | MetaCure, member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. MetaCure develops, produces and sells the DIAMOND therapy, an alternative to insulin, delivered by a proprietary implantable device system. DIAMOND is intended to treat type 2 diabetes in obese patients who are refractory to oral medication. The safety and efficacy of the DIAMOND therapy has been validated in clinical trials encompassing over 300 patients, which demonstrated it is as effective as insulin treatment while avoiding most of the associated side effects and avoiding the inconvenience of frequent blood tests and injections. DIAMOND is delivered by a pacemaker-like device implanted in the abdomen to deliver gentle electrical signals to the stomach when eating, which improves glycemic control and causes weight loss. The system has received CE mark and is approved for sale in Europe, Australia and other international markets. DIAMOND is not approved for use in the USA. For more information visit www.MetaCure.com | MetaCure | Health Care | Health Care Equipment & Services |